From the Guidelines
For individuals with a moderate Framingham risk score, Canadian guidelines recommend a comprehensive approach combining lifestyle modifications and consideration of pharmacotherapy, with a focus on reducing LDL-cholesterol levels and managing other cardiovascular risk factors 1.
Key Recommendations
- Lifestyle interventions should include smoking cessation, regular physical activity, maintaining a healthy diet, limiting alcohol consumption, and achieving a healthy body weight.
- Pharmacotherapy should be considered if LDL-cholesterol is ≥3.5 mmol/L, with statins as first-line therapy, such as atorvastatin 10-20 mg daily or rosuvastatin 5-10 mg daily 1.
- Blood pressure should be maintained below 140/90 mmHg, with antihypertensive medications initiated if lifestyle modifications are insufficient.
- Low-dose aspirin (81 mg daily) may be considered in select patients after weighing bleeding risks against cardiovascular benefits.
Rationale
The Canadian guidelines are based on the principles outlined in the Adult Treatment Panel III (ATP III) report, which emphasizes the importance of therapeutic lifestyle changes (TLC) and pharmacotherapy in managing cardiovascular risk 1.
Monitoring and Follow-up
Regular monitoring is essential, with lipid profiles and cardiovascular risk reassessment recommended annually to ensure that the treatment plan is effective in reducing the overall cardiovascular risk.
Considerations
The approach should be individualized, taking into account the patient's specific risk factors, medical history, and preferences, to ensure that the treatment plan is tailored to their needs and maximizes the reduction of cardiovascular risk 1.
From the Research
Management Recommendations for Moderate Framingham Risk Score
According to Canadian guidelines, individuals with a moderate Framingham risk score require careful management to reduce their risk of cardiovascular disease. The following are some key recommendations:
- The Canadian Cardiovascular Society recommends modifying the Framingham Risk Score (FRS) to better estimate the 10-year risk of cardiovascular disease in Canadians 2.
- For individuals with a moderate Framingham risk score, consideration of additional factors such as biochemical measurements and imaging studies may be necessary to determine the need for statin therapy 3.
- Coronary artery calcium scoring, C-reactive protein measurement, and heart rate recovery and exercise tolerance during exercise stress test may be useful tools for better risk stratification of intermediate-risk patients 4.
- Lifestyle modifications, such as increasing physical activity and physical fitness, may also be beneficial in reducing the risk of cardiovascular disease 5.
- The Canadian guidelines recommend a comprehensive approach to risk assessment and management, taking into account multiple factors beyond just the Framingham risk score 3.
Risk Stratification and Selection for Statin Therapy
The Canadian guidelines recommend the following approach to risk stratification and selection for statin therapy:
- Use the modified Framingham Risk Score to estimate the 10-year risk of cardiovascular disease 2.
- Consider additional factors such as family history of premature cardiovascular disease, biochemical measurements, and imaging studies to determine the need for statin therapy 3.
- Use a practical approach to identify groups of patients at greater risk for atherosclerotic cardiovascular disease than suggested by the FRS, such as those with low-density lipoprotein cholesterol <3.5 mmol/L 3.
Lifestyle Modifications
Lifestyle modifications, such as increasing physical activity and physical fitness, may be beneficial in reducing the risk of cardiovascular disease:
- Regular physical activity and physical fitness have been shown to be inversely and causally associated with coronary heart disease morbidity and mortality 5.
- A graded reduction in the Framingham risk score was observed across low, moderate, and high fitness levels, suggesting that increased physical fitness may be beneficial in reducing cardiovascular risk 5.